ESR1 and breast carcinoma: Literature indicates that treatment of MCF-7-estrogen-receptor-positive breast cancer cell line with either chenodeoxycholate (CDCA) or glycochenodeoxycholate (GCDCA) resulted in opposed effects on proliferation; GCDCA increased MCF7 proliferation, while treatment with CDCA reduced proliferation [66].